Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
We serve patients from Hattiesburg MS, Petal MS, Barron Town MS, Oak Grove MS, West Hattiesburg MS, and surrounding areas
You may also like FAQs Everything you need to know about Vitamin B12 how it works, what to expect, and how to get started with a licensed provider
You should check all the possible interactions with your doctor before starting any medicine
Always talk to a healthcare provider if you have concerns